(410b) Applications of Solid Form Screen for the Purification of Pharmaceutical Compounds | AIChE

(410b) Applications of Solid Form Screen for the Purification of Pharmaceutical Compounds

Authors 

Yang, B. S. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Li, Z. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Yip, K. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Kim, S. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Yee, N. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Krishnamurthy, D. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.
Senanayake, C. - Presenter, Boehringer Ingelheim Pharmaceuticals, Inc.


Crystallization is an important unit operation in the development of pharmaceutical compounds. For the active pharmaceutical ingredients, the screen and selection of optimal development solid form (polymoph/salt/co-crystal) have been commonly practiced across the industry while the compounds are transitions from Research to Development. Nevertheless, crystallization itself is also an important and economical way to purify the crude material for API and process intermediates. This presentation will demonstrate some BI cases where the same ‘toolsets’ used in the API solid form screen are applied on identifying a feasible solid form for the purpose of purification and separation for API’s and process intermediates. The cases of solvent screen, salt formation, including the screen of chiral resolution agent, and/or co-crystal screens will be discussed.

Topics